Lyell Immunopharma Inc
LYEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$404.38M
Close$
$1.03
91.8% downside
Current Fair Value
91.8% downsideOvervalued by 91.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $404.38 Million |
|---|---|
| Enterprise Value | $353.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.06 |
| Beta | -0.06 |
| Outstanding Shares | 21,876,000 |
Return
| Return on Equity | -90.04% |
|---|---|
| Return on Assets | -70.28% |
| Return on Invested Capital | 28.88% |
Valuation & Multiples
| P/E Ratio | -1.54 |
|---|---|
| PEG | 2.86 |
| Price to Sales | - |
| Price to Book Ratio | 1.05 |
| Enterprise Value to Revenue | 11390.22 |
| Enterprise Value to EBIT | 3.9 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-2.37
Average shareholder expectationRevenue Estimate
$5,500
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-2.03
Average shareholder expectationRevenue Estimate
$5,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3425▲ 34.25% |
|---|---|
| Total Calls | 12,000▲ Infinity% |
| Total Puts | 4,110▼ 85.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.06%▲ 7.62% |
|---|---|
| Total Invested | $237.23M▼ 32.28% |
| Investors Holding | 76▲ 6.00% |
ESG Score
No data
About Lyell Immunopharma Inc
189 employees